Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Treatment typically begins with a 2.5 mg once-weekly dose, which is gradually increased in 2.5 mg increments based on glycaemic response and tolerability
Others start with KLOW and transition to GLOW once inflammatory conditions are controlled
Feeling confident in your treatment plan can significantly affect your success
Copper is a vital cofactor for methionine synthase, and its deficiency can impair the enzymes function, disrupting methylation reactions
These symptoms require urgent evaluation to rule out serious cardiac events
Phase 2 trials are primarily designed to assess dose-response relationships and safety signals rather than to definitively establish efficacy at a population level
